Opexa Therapeutics announced that it will deliver two scientific presentations in June on progress of development of monocyte-derived pancreatic islet cells for diabetes.
Opexa Reports First Quarter 2007 Results
THE WOODLANDS, Texas--(BUSINESS WIRE)--May 15, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today reported financial results for the quarter ended March 31, 2007 and provided an update on its progress.
Highlights of the first quarter of 2007 and recent weeks include:
-- Positive top-line data from Phase I/II dose escalation trial with Tovaxin(TM) for multiple sclerosis
-- Opexa announces two scientific presentations to be delivered in June on progress of development of monocyte-derived pancreatic islet cells for diabetes
0 comments:
Post a Comment